Kyle Kathryn W 4

What Happened

• Kyle Kathryn W, Executive Vice President and Chief Legal Officer of LabCorp Holdings, was awarded two equity grants on February 10, 2026: 2,700 employee stock options and 880 Restricted Stock Units (RSUs). Both awards are recorded as derivative grants (code A) with $0 cash paid at grant. The options vest in three equal annual installments beginning Feb 10, 2026; the RSUs vest in three equal annual installments beginning Feb 10, 2027. These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (timely filing).
• Grants: 2,700 employee stock options (right to buy shares) and 880 RSUs (each RSU represents the contingent right to receive one share).
• Vesting: Options vest in three equal annual installments starting 2/10/2026; RSUs vest in three equal annual installments starting 2/10/2027.
• Price/value: Grant listed at $0 (typical for awards); exercise price for the options is not shown in the provided excerpt.
• Shares owned after transaction: The filing lists 880 as the aggregate number of RSUs held by the reporting person; the filing excerpt did not specify total common shares or aggregate options outstanding after the grant.
• No 10b5-1 plan, tax-withholding sale, or late filing is indicated in the provided information.

Context

• Options are a right to purchase shares in the future (they only have value if the stock price exceeds the exercise price). RSUs convert into actual shares when they vest and are typically used as deferred, retention-focused compensation. Because these are grants tied to employment, they are routine executive compensation and do not by themselves indicate buying or selling sentiment.